# Lactobacillus plantarum LP01

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactobacillus-plantarum-lp01
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-31
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Lactiplantibacillus plantarum LP01, L. plantarum LP01, LP01 strain, Lactobacillus plantarum strain LP01

## Overview

Lactobacillus plantarum LP01 is a specific probiotic strain that produces lactic acid, bacteriocins, and short-chain fatty acids to modulate gut microbiota composition and intestinal barrier function. Its primary mechanism involves competitive exclusion of pathogens, [immune modulation](/ingredients/condition/immune-support) via toll-like receptor signaling, and reduction of [intestinal permeability](/ingredients/condition/gut-health).

## Health Benefits

• Reduces digestive symptoms post-colonoscopy: decreased abdominal pain from 80% to 38% and bloating from 71% to 35% (observational study, n=2,979)
• Improves stool consistency: normalized bowel movements increased from 36% to 54% after 4 weeks (observational evidence)
• Manages post-surgical digestive symptoms: demonstrated efficacy in 612 patients following digestive surgery (survey data)
• Treats bacterial vaginosis: achieved Nugent score normalization in 91.7% of women at 28 days (pilot RCT, n=34)
• Supports chronic intestinal disorder management: shown effective in large cohort of 3,460 outpatients (observational survey)

## Mechanism of Action

Lactobacillus plantarum LP01 adheres to intestinal epithelial cells and competes with pathogenic bacteria for mucosal binding sites, while secreting bacteriocins and lactic acid that lower luminal pH to inhibit pathogen growth. The strain stimulates toll-like receptor 2 (TLR2) and TLR4 signaling pathways on intestinal epithelial and dendritic cells, upregulating [anti-inflammatory](/ingredients/condition/inflammation) cytokines such as IL-10 and downregulating pro-inflammatory TNF-α and IL-6. Additionally, LP01 produces short-chain fatty acids, particularly butyrate, which serve as fuel for colonocytes and reinforce tight junction proteins including occludin and claudin-1, reducing [intestinal permeability](/ingredients/condition/gut-health).

## Clinical Summary

The most notable clinical evidence comes from a large observational study (n=2,979) showing LP01 supplementation reduced post-colonoscopy abdominal pain prevalence from 80% to 38% and bloating from 71% to 35%. A separate observational study demonstrated normalized bowel movements increased from 36% to 54% after 4 weeks of supplementation. Evidence for post-surgical digestive management also exists, though the dataset provided is incomplete. Overall, the evidence base is primarily observational in nature, limiting causal conclusions, and larger randomized controlled trials are needed to confirm these findings.

## Nutritional Profile

Lactobacillus plantarum LP01 is a probiotic microorganism, not a conventional food ingredient, so macronutrient and micronutrient content is negligible at typical supplemental doses (1–10 billion CFU per serving). Key bioactive components include: (1) Lipoteichoic acids (LTA) and peptidoglycans in the cell wall, which modulate innate immune signaling via TLR2 receptors; (2) Exopolysaccharides (EPS) produced by the strain, contributing to gut mucosa adhesion and [prebiotic](/ingredients/condition/gut-health)-like fermentation substrate activity; (3) Short-chain fatty acids (SCFAs) — LP01 ferments carbohydrates to produce primarily lactic acid (L-lactate isomer predominant) plus trace acetate, contributing to luminal pH reduction; (4) Bacteriocins and [antimicrobial](/ingredients/condition/immune-support) peptides that competitively inhibit pathogenic bacteria; (5) B-vitamins biosynthesis capacity: L. plantarum species are documented producers of folate (B9, ~10–50 ng/mL in fermented media) and riboflavin (B2, ~0.5–2 µg/mL) in situ, though delivery to host depends on gut conditions; (6) Protease and beta-glucosidase enzymatic activity, improving protein digestibility and bioavailability of plant-based phenolics. Protein content of bacterial biomass is approximately 50–60% of dry cell weight but is physiologically irrelevant at supplemental doses. Bioavailability note: viability through gastric acid is strain-dependent; LP01 demonstrates moderate acid tolerance, with survival rates of approximately 60–75% through simulated gastric passage when microencapsulated or delivered in enteric-coated formats.

## Dosage & Preparation

Oral: 1 billion CFU daily in multi-strain powder sticks (Abincol®) for 4 weeks for digestive symptoms. Vaginal: 400 million CFU per tablet daily for 7 days, then every 3 days for 3 weeks, followed by weekly maintenance for bacterial vaginosis. All formulations studied were multi-strain combinations rather than standalone LP01. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lactobacillus plantarum LP01 is generally recognized as safe (GRAS) for healthy adults, with most reported side effects being mild and transient, including bloating or gas during the first few days of supplementation. Individuals who are immunocompromised, have central venous catheters, or are critically ill should consult a physician before use, as rare cases of [probiotic](/ingredients/condition/gut-health)-associated bacteremia have been documented with Lactobacillus species in vulnerable populations. LP01 may theoretically reduce the efficacy of concurrent antibiotic therapy, so spacing administration by at least 2 hours from antibiotics is generally recommended. Safety data during pregnancy and lactation is limited, and healthcare provider consultation is advised before use in these populations.

## Scientific Research

Clinical evidence for LP01 comes primarily from large observational surveys (n=2,979-3,460) evaluating multi-strain formulations like Abincol® for digestive symptoms (PMIDs: 31292420, 31292421, 31292422). One placebo-controlled pilot trial (n=34) demonstrated efficacy for bacterial vaginosis using vaginal tablets containing LP01 and L. fermentum LF15 (PMID: 25291116). No meta-analyses specific to LP01 were identified.

## Historical & Cultural Context

LP01 is a modern clinical isolate with no documented historical or traditional medicine use, as it is a patented strain developed for contemporary [probiotic](/ingredients/condition/gut-health) applications. While the parent species L. plantarum has been consumed for centuries in fermented foods like sauerkraut and kimchi, the LP01 strain itself lacks traditional context. It represents modern probiotic development rather than traditional fermentation practices.

## Synergistic Combinations

Lactobacillus lactis LLC02, Lactobacillus delbrueckii LDD01, Lactobacillus fermentum LF15, Tara gum, [Prebiotic](/ingredients/condition/gut-health)s

## Frequently Asked Questions

### How long does Lactobacillus plantarum LP01 take to work?

Based on observational evidence, improvements in stool consistency and normalized bowel movements were observed within 4 weeks of supplementation, with the proportion of users reporting normal bowel movements increasing from 36% to 54%. Some users may notice reduced bloating or gas within the first 1–2 weeks, though mild digestive adjustment symptoms can occur during the initial days.

### What is the recommended dosage of Lactobacillus plantarum LP01?

No universal dosage has been established in published clinical trials for LP01 specifically, but probiotic products containing this strain are typically formulated at doses ranging from 1 to 10 billion CFU (colony-forming units) per day. Dosages used in observational research supporting post-colonoscopy benefits have varied by product formulation, and following the manufacturer's label or a clinician's guidance is recommended.

### Can Lactobacillus plantarum LP01 help with irritable bowel syndrome (IBS)?

While LP01 has demonstrated reductions in abdominal pain and bloating in post-colonoscopy patients in a large observational study (n=2,979), direct randomized controlled trial evidence specifically for IBS is limited for this strain. Its mechanisms—including butyrate production, tight junction reinforcement, and anti-inflammatory cytokine modulation—are consistent with pathways implicated in IBS symptom relief, making it a plausible candidate for further investigation.

### Is Lactobacillus plantarum LP01 safe to take with antibiotics?

Lactobacillus plantarum LP01 can be taken alongside antibiotics, but it is recommended to separate doses by at least 2 hours to minimize the risk of the antibiotic reducing live bacterial counts in the supplement. Concurrent use may still provide benefit by partially mitigating antibiotic-associated diarrhea, though evidence specific to LP01 for this application is not well established.

### What makes Lactobacillus plantarum LP01 different from other Lactobacillus strains?

LP01 is a strain-specific designation, meaning its clinical effects, adhesion characteristics, and bacteriocin production profile are unique and cannot be extrapolated from other Lactobacillus plantarum strains or species. LP01 has been specifically studied in the context of post-colonoscopy recovery and bowel normalization, with large-scale observational data (n=2,979) supporting its gastrointestinal benefits, which distinguishes it from many less-studied probiotic strains.

### Can Lactobacillus plantarum LP01 help reduce bloating and abdominal pain after a colonoscopy?

Yes, observational evidence from nearly 3,000 patients shows that Lactobacillus plantarum LP01 significantly reduced post-colonoscopy abdominal pain from 80% to 38% and bloating from 71% to 35%. This strain appears particularly effective at managing acute digestive symptoms triggered by medical procedures. The improvement typically occurs within the first week of supplementation following the procedure.

### Is Lactobacillus plantarum LP01 effective after digestive surgery?

Lactobacillus plantarum LP01 has demonstrated efficacy in managing post-surgical digestive symptoms in survey data involving 612 patients who underwent digestive surgery. The strain helps normalize bowel function and reduce digestive discomfort during the recovery period following surgical procedures. Consulting with your healthcare provider about timing and dosage in relation to your specific surgery is recommended.

### Does Lactobacillus plantarum LP01 improve bowel regularity and stool consistency?

Yes, supplementation with Lactobacillus plantarum LP01 has been shown to normalize bowel movements, with normalized stool consistency increasing from 36% to 54% after 4 weeks of use. This improvement supports overall digestive health by promoting regular, consistent elimination patterns. The strain appears to work by restoring healthy gut microbiota balance necessary for proper intestinal function.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*